Qiagen : CMD left a positive impression – mid-term outlook fits well with our earnings model
>2024-2028 guidance above market expectations - At its CMD, Qiagen's new mid-term guidance was clearly in the focus. For the first time, the company provided a top-line guidance (2024-2028 CAGR of 7%) that reflects above-market growth rates for all five strategic pillars and came in above consensus estimates of 6.6% for this period. At the same time, the company forecasts an adjusted operating profit margin of at least 31% CER in 2028 compared to market expectations o...Qiagen is provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. Co.'s sample technologies process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software interprets data. Automation solutions unite these together in molecular testing workflows. Co. provides these workflows to four classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Co. markets its products in more than 130 countries.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.